|Screening for epidermal growth factor receptor mutations in lung cancer|
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
|A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer|
R Rosell, J Gomez-Codina, C Camps, J Maestre, J Padille, A Canto, ...
New England Journal of Medicine 330 (3), 153-158, 1994
|Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer|
RVN Lord, J Brabender, D Gandara, V Alberola, C Camps, M Domine, ...
Clinical Cancer Research 8 (7), 2286-2291, 2002
|hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer|
C Camps, FM Buffa, S Colella, J Moore, C Sotiriou, H Sheldon, AL Harris, ...
Clinical cancer research 14 (5), 1340-1348, 2008
|Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer|
M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ...
Journal of clinical oncology 25 (19), 2747-2754, 2007
|Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients|
R Rosell, KD Danenberg, V Alberola, G Bepler, JJ Sanchez, C Camps, ...
Clinical Cancer Research 10 (4), 1318-1325, 2004
|Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial|
R Rosell, J Gómez-Codina, C Camps, JJ Sánchez, J Maestre, J Padilla, ...
Lung cancer 26 (1), 7-14, 1999
|The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer|
RM Bremnes, T Dønnem, S Al-Saad, K Al-Shibli, S Andersen, R Sirera, ...
Journal of thoracic oncology 6 (1), 209-217, 2011
|Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood|
RM Bremnes, C Camps, R Sirera
Lung cancer 51 (2), 143-158, 2006
|Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer|
D Isla, C Sarries, R Rosell, G Alonso, M Domine, M Taron, ...
Annals of oncology 15 (8), 1194-1203, 2004
|microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer|
FM Buffa, C Camps, L Winchester, CE Snell, HE Gee, H Sheldon, ...
Cancer research 71 (17), 5635-5645, 2011
|Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer|
E Felip, R Rosell, JA Maestre, JM Rodríguez-Paniagua, T Morán, ...
Journal of Clinical Oncology 28 (19), 3138-3145, 2010
|Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients|
H Cortes-Funes, C Gomez, R Rosell, P Valero, C Garcia-Giron, A Velasco, ...
Annals of oncology 16 (7), 1081-1086, 2005
|The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis|
HE Gee, FM Buffa, C Camps, A Ramachandran, R Leek, M Taylor, M Patil, ...
British journal of cancer 104 (7), 1168-1177, 2011
|Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III …|
V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ...
Journal of clinical oncology 21 (17), 3207-3213, 2003
|Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival|
H Choudhry, A Albukhari, M Morotti, S Haider, D Moralli, J Smythies, ...
Oncogene 34 (34), 4482-4490, 2015
|hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer|
HE Gee, C Camps, FM Buffa, S Patiar, SC Winter, G Betts, J Homer, ...
Cancer 116 (9), 2148-2158, 2010
|The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer|
RM Bremnes, K Al-Shibli, T Donnem, R Sirera, S Al-Saad, S Andersen, ...
Journal of Thoracic Oncology 6 (4), 824-833, 2011
|Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients|
R De las Peñas, M Sanchez-Ronco, V Alberola, M Taron, C Camps, ...
Annals of Oncology 17 (4), 668-675, 2006
|Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF …|
M Martin, A Villar, A Sole-Calvo, R Gonzalez, B Massuti, J Lizon, ...
Annals of Oncology 14 (6), 833-842, 2003